drugset / Trial / NCT03757403
RDD1609 as a Treatment for Idiopathic Pruritus Ani
RandomizedCrossoverTriple-blindTreatment
Summary
This is a double-blind, randomized, placebo-controlled, crossover trial, to test the hypothesis that RDD1609 is effective in treating idiopathic pruritus ani.
Timeline
- Start
- 2020-05-01
- Primary completion
- 2020-11-30
- Completion
- 2020-12-31
Outcome
Outcome not reported
Stopped: “Covid-19”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RDD1609 | Unknown | — | Topical |
| Background | Mebendazole | Small molecule | 100 mg | — |
Indications
No indication recorded.